Atara Biotherapeutics Inc (ATRA) Institutional Ownership Tracker (Q2 2026)

ATRA ranks #7027 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ATRA is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

36 institutions disclose a position in ATRA, but none treat it as a major bet — even EcoR1 Capital, LLC, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

ATRA is down 4.9% today, but institutions show net buying of $21.9M this quarter — a divergence between today's price move and the underlying institutional flow.

ATRA reported a net loss of $16.7M over the trailing twelve months.

• Not yet profitable — net loss of $16.7M over the trailing twelve months
• Revenue declined 96.7% year over year
• Net income declined year over year, from $5.8M to -$16.7M
• Operating cash flow was negative, using $50.9M in cash
• Current ratio of 0.82x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)